Answer
Hypertrophic cardiomyopathy (HCM)
Updated 14 November 2026
HCM is an inherited disease of the heart muscle in which the left ventricle — usually the interventricular septum — is abnormally thick without another explanation such as hypertension, aortic stenosis, amyloidosis or Fabry disease. It is the most common inherited cardiomyopathy: prevalence is classically quoted as ~1 in 500, with contemporary screening/registry estimates of roughly 1:200 to 1:350; most affected people remain undiagnosed. It is the classic cause of sudden cardiac death in young athletes, although the attributable fraction varies widely between registries and countries (from single digits to roughly a third in some US athlete series). In contemporary cohorts, annual arrhythmic mortality is <0.5%/year.
Definition
Per the 2024 AHA/ACC multisociety guideline (reaffirmed as current in 2025; no substantive US revision has appeared as of November 2026), the 2023 ESC cardiomyopathy guideline, and 2026 European Society of Cardiology/European Journal of Heart Failure (EJHF) expert consensus documents (one on diagnosis and management, Eur J Heart Fail 2026;28:299–314; a companion one on comprehensive evaluation, Martens et al.):
- Adults: maximal end-diastolic LV wall thickness ≥15 mm on echo or cardiac MRI, unexplained by loading conditions or infiltrative/storage disease.
- 13–14 mm is diagnostic with a first-degree relative with HCM or a pathogenic/likely pathogenic sarcomere variant.
- Children: body-surface-area-adjusted wall thickness z-score >2.5, or >2 with family history or a pathogenic variant.
- Hypertrophic phenocopies and athlete's heart must be excluded.
Cause and genetics
Usually autosomal dominant sarcomere disease, most often MYH7 and MYBPC3. A pathogenic variant is found in roughly 30–60% of patients (higher in familial/early-onset disease); the rest are genotype-negative but clinically have HCM. Penetrance is incomplete and expression variable, so first-degree relatives need clinical screening and cascade genetic testing. Variant interpretation is not static: a 2026 reanalysis of 2,154 index cases found ~13% of variants reclassified (about 7.5% with clinically meaningful change), altering genetic status in ~4% of people — supporting periodic re-review rather than a "one-and-done" test.
Pathophysiology
Hypercontractile sarcomeres, impaired relaxation/diastolic dysfunction, myocyte disarray, fibrosis, microvascular ischemia, and mitral valve systolic anterior motion causing dynamic LVOT obstruction. About half of patients have obstruction at rest and up to two-thirds at rest or with provocation (gradient ≥30 mmHg at rest, ≥50 mmHg provoked); the rest have nonobstructive HCM. Atrial fibrillation and ventricular arrhythmias are common.
Symptoms and signs
Many people are asymptomatic for life. Others have exertional dyspnea, chest pain, palpitations, presyncope/syncope, fatigue, or present with cardiac arrest. The classic murmur is a harsh systolic murmur at the left sternal border that loudens with Valsalva/standing and softens with squatting.
Diagnosis
ECG (LVH, deep narrow Q waves, repolarization changes) plus echocardiography; cardiac MRI for maximal wall thickness, apical aneurysm and scar/fibrosis; ambulatory ECG monitoring; stress echocardiography for provocable obstruction; genetic testing and family cascade screening. Because most cases are undiagnosed, screening tools are being studied — AI-ECG algorithms such as Viz HCM, the first FDA-authorised ECG algorithm for HCM detection (De Novo clearance, September 2023), and point-of-care echocardiography screening; these complement, not replace, imaging-based diagnosis.
Treatment
- Asymptomatic low-risk patients may need only surveillance.
- Beta-blockers remain guideline first-line for symptomatic obstruction; nondihydropyridine calcium-channel blockers (verapamil, diltiazem) are alternatives, and disopyramide can be added. Avoid vasodilators and aggressive diuresis in obstructive HCM.
- Cardiac myosin inhibitors for symptomatic obstructive HCM: mavacamten (Camzyos) and aficamten (Myqorzo).
- Mavacamten: FDA-approved 2022; label extended 30 September 2026 to children aged 12–<18 years weighing ≥30 kg, based on SCOUT-HCM (44 adolescents randomised 1:1, 43 completed the 28-week blinded phase; mean Valsalva gradient change −48.1 mmHg at week 56 in the mavacamten→mavacamten arm; NEJM 2026;395:362–373) — the first FDA-approved drug for paediatric oHCM and, per the sponsor, the broadest indication of any cardiac myosin inhibitor. The 56-week data presented 6 November 2026 at the HCMS Scientific Sessions/AHA showed sustained benefit, no patient with LVEF <50% at any point, and no new safety signals; the open-label extension runs to 144 weeks. EU label remains adults only. Adult long-term data presented at AHA 2026 included 4-year CAMZYOS REMS findings consistent with trials and MAVA-LTE cardiac MRI showing favourable structural/functional remodelling over up to 5 years.
- Aficamten: approved by FDA (19 December 2025), China, European Commission (Feb 2026), UK MHRA with NICE TA1181 (add-on to optimised standard care) and Health Canada (Notice of Compliance, 19 October 2026); launched in the US and Germany, with a UK launch planned for Q4 2026. In MAPLE-HCM, aficamten monotherapy beat metoprolol for peak VO₂ (+2.3 mL/kg/min: +1.1 vs −1.2) and other disease-burden measures. A supplemental application to add these head-to-head data to the US label had a PDUFA date of 14 November 2026 — the decision was still pending at the time of writing (the only US supplement acted on so far is the February 2026 REMS/label-alignment approval). Even if granted, a label change does not by itself displace beta-blockade as guideline first-line therapy. The French HAS issued a significant medical-benefit (SMR) opinion with an ASMR III (moderate added benefit) rating on 10 November 2026. A supplemental filing for nonobstructive HCM is still planned for Q4 2026 (EU Type II variation early 2027).
- Both are dispensed via REMS with echocardiographic LVEF monitoring (aficamten: do not initiate if LVEF <55%). Mavacamten carries boxed warnings for systolic dysfunction and fetal risk and has CYP-mediated drug interactions. Long-term FOREST-HCM data (410 patients; now published in the Journal of Cardiac Failure) found LVEF <50% in 2.9% (2.1 events/100 patient-years), none <40%, with events transient, asymptomatic and reversible after dose reduction or interruption; borderline LVEF 50–55% was clinically benign.
- In nonobstructive HCM, mavacamten was neutral (ODYSSEY-HCM), whereas aficamten improved peak VO₂ (+0.64 vs −0.03 mL/kg/min) and KCCQ scores in ACACIA-HCM (NEJM, Aug 2026), with more LVEF <50% (10.5% vs 0.8%) and no reduction in cardiovascular events. New HCMS/AHA 2026 analyses: a prespecified CMR substudy showed significant reductions in LV mass index and wall thickness vs placebo at 36 weeks, driven by cellular mass with no significant change in extracellular matrix/fibrosis, paralleling falls in NT-proBNP and hs-troponin I; KCCQ-OSS improved 4.0 points more than placebo, with 53% of aficamten patients improving in ≥3 clinical domains vs 13% on placebo. Notably, these gains faded within about four weeks of drug withdrawal, so treatment appears to be disease-modifying only while continued. Not yet approved for this indication.
- ICD for secondary prevention, or primary prevention with ≥1 major risk factor: premature HCM-related sudden death in a close relative, unexplained arrhythmic syncope, wall thickness ≥30 mm, apical aneurysm with transmural scar, LVEF <50%, or NSVT; extensive LGE (~≥15% of LV mass) is an additional marker. European practice uses HCM Risk-SCD 5-year estimates. Decisions are shared.
- Septal reduction therapy — surgical myectomy or alcohol septal ablation — for drug-refractory obstruction at experienced centres.
- Anticoagulation for atrial fibrillation, generally irrespective of CHA₂DS₂-VASc score.
- Exercise: mild-to-moderate recreational exercise is encouraged; vigorous and competitive sport may be considered after expert evaluation and shared decision-making. Universal restriction is no longer recommended.
Prognosis
Highly variable: many patients have a normal lifespan, but HCM carries risks of sudden death, heart failure, atrial fibrillation and stroke. The 2026 NHLBI HCM Registry analysis (JAMA, 2,698 patients, ~6.9-year follow-up) showed cardiac MRI measures and NT-proBNP improve prediction of composite and arrhythmic events beyond conventional markers: the primary composite model included LGE as a percentage of LV mass (HR 1.86 per 10-unit increase), LV mass index, LV end-systolic volume index, heart-failure history and log NT-proBNP (C-statistic 0.77), with LGE ≥9% of LV mass marking a substantially higher event rate. These tools are not yet in guidelines.
Emerging
Gene therapy (TN-201, AAV9 MYBPC3 replacement) continues to show early signals of benefit in MyPEAK-1 — June 2026 interim data (6 evaluable patients) reported reductions in LV mass index in all six, reduced wall thickness in five, ≥1 NYHA class improvement in five, and KCCQ-CSS gains of 12–56 points, with biopsy evidence of transgene expression and rising MyBP-C protein; pivotal-trial design discussions are expected around end-2026. Aficamten in adolescents (CEDAR-HCM) has completed enrolment of its adolescent cohort, with topline data in 2027. Next-generation agents include:
- HRS/BHB-1893 (Braveheart Bio/Hengrui): 52-week open-label extension in 42 patients (AHA 2026) showed peak VO₂ +2.7 mL/kg/min, KCCQ-CSS +17.3 points, 67% of patients below a 30 mmHg Valsalva gradient by week 1 and 90% at ≥1 visit, 57% still on the 40 mg twice-daily starting dose at week 52, and no serious adverse events (two transient site-measured LVEF dips to 48–49% resumed at lower dose). A companion analysis — preclinical models plus 84 patients with nonobstructive HCM — suggested improved relaxation and filling with preserved pumping, hinting at a role beyond obstruction. The global phase 3 LIONHEART-HCM vs metoprolol is now enrolling (primary endpoint peak VO₂ at week 24; week-12 gradient interim in H2 2027); a fixed-dose phase 2b (TRUEHEART-HCM) and a phase 3 in nonobstructive HCM (NOBLEHEART-HCM) are planned for H1 2027. Hengrui's China phase 3 is fully enrolled, with topline in H1 2027.
- EDG-7500, a cardiac sarcomere modulator: phase 3 STRATUS-HCM (obstructive and nonobstructive HCM, 2:1 randomisation, tolerability-based dose escalation without routine safety echoes) is on track to start by Q4 2026.
- Sotagliflozin (SONATA-HCM completed enrolment July 2026; AHA 2026 ex vivo data show afterload-dependent reduction in work in living human HCM myocardial slices; topline expected Q1 2027) and ninerafaxstat (FORTITUDE-HCM, phase 2b in nonobstructive HCM; primary completion estimated December 2026).
This is general educational information, not medical advice.
Update history
- Auto-checkVersion 160 sources · AI-generated
- Auto-checkVersion 150 sources · AI-generated
- Auto-checkVersion 140 sources · AI-generated
- Auto-checkVersion 130 sources · AI-generated
- Auto-checkVersion 120 sources · AI-generated
- Auto-checkVersion 110 sources · AI-generated
- Auto-checkVersion 100 sources · AI-generated
- Auto-checkVersion 90 sources · AI-generated
- Auto-checkVersion 80 sources · AI-generated
- Auto-checkVersion 70 sources · AI-generated
- Auto-checkVersion 60 sources · AI-generated
- Auto-checkVersion 50 sources · AI-generated
- Auto-checkVersion 40 sources · AI-generated
- Auto-checkVersion 30 sources · AI-generated
- Auto-checkVersion 20 sources · AI-generated
- Initial answerVersion 10 sources · AI-generated